Infectious Diseases
COVID-19 has raised the importance of research into fighting infectious diseases that threaten populations.
COVID-19 vaccines: Post-authorisation safety surveillance
This whitepaper explores the multifaceted challenges of COVID-19 post-authorisation safety surveillance studies and how business intelligence tools can benefit these efforts.
Assessing strategies for mitigating infectious diseases
Public health officials turn to evidence as the basis for their health policies to control the spread of infections. However, many nuanced factors can influence variations in the number of infections caused by a single infected individual.
Watch the webinar: An introduction to infectious disease modelling
In this whitepaper, we explain the basic measures used to quantify infectious disease transmission and introduce the principles of dynamic modelling to inform the selection of the most effective and cost-efficient strategies for mitigating infectious diseases.
Fortifying vaccines: Preparation and prevention against future infectious disease epidemics
This whitepaper presents infrastructural and strategic considerations for strengthening vaccine development so that the medical community will be prepared to respond to future pandemics and novel diseases.
Antimicrobial resistance
The World Health Organization calls antimicrobial resistance, resulting from the overuse of antibiotics or other drugs, one of the top 10 public health threats. In fact, the next global pandemic could be another novel respiratory pathogen of zoonotic origins or a multidrug resistant strain of a previously eradicated pathogen.
In this whitepaper we provide a framework for understanding the antimicrobial crisis and the role healthcare and biopharma industries have to play in mitigating the impact of future pandemics.
The evolution of HIV treatments
HIV is highly heterogeneous, creating barriers to diagnosing and treating the disease. Moreover, the HIV epidemic varies by region and country, necessitating different clinical research strategies across geographies. In this whitepaper, we discuss opportunities for addressing these challenges, best practices for managing infectious disease clinical trials and recent developments in HIV treatment.
Pandemic respiratory vaccine clinical trials: A departure from business as usual
Vaccine trials for respiratory viruses, even in the best of circumstances, present a number of operational challenges for researchers, many of which are exacerbated in the face of a pandemic created by a novel virus. We focus on the corresponding success factors that can keep pandemic respiratory vaccine trials running at optimal speed and efficiency.
HIV infographic
HIV treatments: What has been achieved?
Before antiretroviral treatment availability, life expectancy for a person living with HIV was reduced by approximately 12.5 years. Now, this same individual will have near-normal life expectancy.
Infectious diseases and vaccines blogs
The race to develop combination vaccines – and the importance of indirect effects
A development race is currently underway in the field of combination vaccines, with a number of influential pharmaceutical and biotech companies pursuing combination vaccines targeting influenza and COVID-19.
Disease surveillance in low- and middle-income countries
Disease surveillance and reporting is critical to public health, enabling faster and better response to infectious disease outbreaks.
Disease surveillance and innovative vaccines
Learn about current approaches to disease surveillance and why they are important for the advancement of vaccine development in this blog.
Pre-emptive vaccine research to improve EID response
This blog explores strategies for strengthening vaccine development so that the medical community is better prepared to respond to future epidemics.
From clinician visits to data analysis: the challenges and solutions in COVID vaccine pharmacovigilance
Learn more about the challenges and solutions in assessing the long-term effects of Covid and Covid vaccines in this blog.
Combatting AMR with new tools to diagnose and treat infectious disease
The employment of antimicrobials to fight previously devastating microbial diseases, such as tuberculosis, meningitis and pneumonia has been a transformative medical achievement.
ICON Joins UNICEF Corporate Vaccine Alliance
ICON is one of seven leading Irish companies that just endorsed an open letter urging fellow corporate leaders to join the UNICEF Corporate Vaccine Alliance.
Battling HIV on many fronts
Discover how in-home services and a global development strategy can help us get closer to more effective treatments.
Infectious diseases and vaccines media contributions
-
Media article: A trusted partner for clinical development
ICON CEO Steve Cutler chats with Newsweek, on ICON’s role in the development of much needed medicines. The interview (page 12 of PDF) is part of a special report on Ireland.
-
Media article: Implications of COVID-19 on statistical design and analyses of clinical studies
Tim Victor, Head of Biostatistics at ICON, considers the challenges and risks to statistical integrity and how they can be mitigated.
-
Media article: Smart people: Dr. Steve Cutler
PharmaTimes talks to Dr Steve Cutler, CEO at ICON plc, about the impact of the COVID pandemic and challenges of running large-scale vaccine trials.
-
Media article: Global collaboration: Irish company ICON on scaling up COVID-19 vaccine trials
An interview in which Steve Cutler gives a short overview of ICON and describes the company’s role in the Pfizer/BioNTech trial, explaining how the FDA played a critical role in expediting regulatory approvals.
-
Media article: The effect of Covid-19 solutions on the clinical trials process
Shelley McLendon, VP of Project Management, Vaccines and Infectious Diseases, outlines best practices that can keep trials running at optimal speed and efficiency, and the benefits of adopting a strategic partnership.
-
Media article: A challenge of pandemic proportions
ICON CEO Steve Cutler, discusses running the Pfizer / BioNTech vaccine trial, and how it proved the value of partnership, and the key role of technology.
-
Media article: US Regulators question AstraZeneca vaccine trial data
ICON's Dr. Andrew Garrett, Executive Vice President of Scientific Operations, weighs in on potential safety issues with the AstraZeneca COVID-19 vaccine.
-
Media article: What does it really take to conduct a vaccine trial at scale?
Dr Nuala Murphy, President of Clinical Services, talks exclusively to Pharmafield about the Pfizer/BioNTech COVID-19 vaccine trial and the implications this has on the future of drug development.
Receive more insights on infectious diseases and vaccines from ICON
Please visit ICON's Preference Centre and select 'Infectious Diseases and Vaccines' under 'Therapeutic Areas of Interest' to receive new insights on infectious diseases and vaccines.
Infectious diseases and vaccines services
ICON’s extensive Infectious Disease expertise enables us to consistently select the best sites, expedite start-up timelines, and achieve enrolment targets for our clients. We apply proven strategies to clinical trials that minimise risk and generate high-quality, reliable data reducing the time and cost of bringing new therapies to market.